Breaking News

You are here » Indian-Commodity  :  Commodities  :  Jeera Commodities Dealing Better


Jeera Commodities Dealing Better

Jeera commodities are dealing better on the back of a few smaller amount of acquiring as well as appearance of higher quality plants also was offering assist to costs. Additional , professionals assume dealing exercises to increase tremendously in forthcoming weeks as the appearance will likely shoot up as well as possibility of export too obtaining.

The plan of May supply was buying and selling at Rs 14850.00, upward 0.13% or Rs 20.00 from the last ending of Rs 14830.00. The available interest associated with deal was standing at 17394 lots.

The deal for June supply was dealing the same at Rs 15425.00. The available interest associated with the deal was standing at 19581 a lot on NCDEX.

Related News

View all news

BT Cotton Seeds Businesses Targeting Earnings Of Rs 700 Crore This Season

BT Cotton seeds organizations are targeting earnings of Rs 700 cr this season as a result of a rise ......

Gold Challenges To Maintain Earlier Increases As The Problems In Europe Prolongs

Gold prices surrounded reduce on Monday because the euro solved their deficits in opposition to the ......

Copper Seems To Lengthen Uptrend As Dollar Recoils

Copper rates were able to lengthen the uptrend for 3rd instantly period on Monday, as traders proved......

Top News

View all news

Reliance Power's arm wins arbitration award against NACC

Reliance Power's Wholly Owned Subsidiary -- Sasan Power has won an arbitration award against North American Coal Corporation (NACC). This is a major milestone in this arbitration with the award received......

Tata Steel's arm signs agreement to divest entire stake in Black Ginger 461

Tata Steel's wholly owned indirect subsidiary -- TS Global Minerals Holdings Pte has entered into an agreement to divest its entire stake in its wholly owned step down subsidiary Black Ginger 461 Pty which......

Biocon, Mylan N.V. receive positive approval for Ogivri

Biocon and Mylan N.V. have been issued a positive opinion recommending approval of Ogivri, a biosimilar to Roche's Herceptin (trastuzumab) by the European Medicines Agency's Committee for Medicinal Products......